Notice Pursuant to the National Cooperative Research and Production Act of 1993-Medical CBRN Defense Consortium, 57616 [2017-26215]

Download as PDF 57616 Federal Register / Vol. 82, No. 233 / Wednesday, December 6, 2017 / Notices changes in its membership. The notifications were filed for the purpose of extending the Act’s provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, Dell Technologies, Santa Clara, CA; and Juniper Networks, Sunnyvale, CA, have withdrawn as parties to this venture. No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and Open Platform for NFV Project intends to file additional written notifications disclosing all changes in membership. On October 17, 2014, Open Platform for NFV Project filed its original notification pursuant to Section 6(a) of the Act. The Department of Justice published a notice in the Federal Register pursuant to Section 6(b) of the Act on November 14, 2014 (79 FR 68301). The last notification was filed with the Department on August 23, 2017. A notice was published in the Federal Register pursuant to Section 6(b) of the Act on September 18, 2017 (82 FR 43568). Patricia A. Brink, Director of Civil Enforcement, Antitrust Division. [FR Doc. 2017–26216 Filed 12–5–17; 8:45 am] BILLING CODE P DEPARTMENT OF JUSTICE Antitrust Division daltland on DSKBBV9HB2PROD with NOTICES Notice Pursuant to the National Cooperative Research and Production Act of 1993—Heterogeneous System Architecture Foundation Notice is hereby given that, on November 14, 2017, pursuant to Section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 et seq. (‘‘the Act’’), Heterogeneous System Architecture Foundation (‘‘HSA Foundation’’) has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act’s provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, Institute of Computer Architecture, School of ZZCS, Peking University, Beijing, PEOPLE’S REPUBLIC OF CHINA; China Electronics Standardization Institute (CESI), Beijing, PEOPLE’S REPUBLIC VerDate Sep<11>2014 18:07 Dec 05, 2017 Jkt 244001 OF CHINA; Nanjing University of Science and Technology, Nanjing, PEOPLE’S REPUBLIC OF CHINA; Xiamen University, Xiamen, PEOPLE’S REPUBLIC OF CHINA; Huaqiao University, Xiamen, PEOPLE’S REPUBLIC OF CHINA; Jimei University (Engineering College), Xiamen, PEOPLE’S REPUBLIC OF CHINA; Xiamen University of Technology, Xiamen, PEOPLE’S REPUBLIC OF CHINA; and Zhejiang University, Zhejiang, PEOPLE’S REPUBLIC OF CHINA, have been added as parties to this venture. Also, LG Electronics, Inc., Seoul, KOREA; Swarm64 GMBH, Berlin, GERMANY; Allinea Software Ltd., Warwick, UNITED KINGDOM; MediaTek USA Inc., Hsinchu City, TAIWAN; and Ceva Inc., Mountain View, CA, have withdrawn as parties to this venture. No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and HSA Foundation intends to file additional written notifications disclosing all changes in membership. On August 31, 2012, HSA Foundation filed its original notification pursuant to Section 6(a) of the Act. The Department of Justice published a notice in the Federal Register pursuant to Section 6(b) of the Act on October 11, 2012 (77 FR 61786). The last notification was filed with the Department on March 13, 2017. A notice was published in the Federal Register pursuant to Section 6(b) of the Act on April 4, 2017 (82 FR 16418). Patricia A. Brink, Director of Civil Enforcement, Antitrust Division. [FR Doc. 2017–26217 Filed 12–5–17; 8:45 am] BILLING CODE P DEPARTMENT OF JUSTICE Antitrust Division Notice Pursuant to the National Cooperative Research and Production Act of 1993—Medical CBRN Defense Consortium Notice is hereby given that, on October 13, 2017, pursuant to Section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 et seq. (‘‘the Act’’), Medical CBRN Defense Consortium (‘‘MCDC’’) has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its PO 00000 Frm 00048 Fmt 4703 Sfmt 9990 membership. The notifications were filed for the purpose of extending the Act’s provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, Medicago, USA, Durham, NC; Lynntech, Inc., College Station, TX; Cepheid, Sunnyvale, CA; Valaria Technical Consultants, LLC, Westminster, MD; Integrity Bio, Inc., Camarillo, CA; California Institute of Technology, Pasadena, CA; General Atomics, San Diego, CA; Conductive Technologies, Inc., York, PA; Dyadic International, Jupiter, FL; Excet, Inc., Springfield, VA; INanoBio Inc., Tempe, AZ; SynerGene Therapeutics, Inc., Potomac, MD; Rutgers University, New Brunswick, NJ; Celdara Medical, LLC, Lebanon, NH; Janus-I Science, Inc., Carlsbad, CA; Pharm-Olam International Ltd, Houston, TX; Vaxess Technologies, Inc., Allston, MA; HORIBA Instruments, Inc., Edison, NY; Sentinel Analytics Software, Inc., Davis, CA; Booz Allen Hamilton, McLean, VA; Tonix Pharmaceuticals, New York, NY; Just Biotherapeutics, Inc., Seattle, WA; General Electric Company, GE Global Research, Niskayuna, NY; The University of North Carolina Chapel Hill, Chapel Hill, NC; and Rector and Visitors of the University of Virginia, Charlottesville, VA, have been added as parties to this venture. Also, Tech62, Fairfax, VA; Joint Research and Development, Inc., Stafford, VA; ProModel Corporation, Allentown, PA; and Proteos, Kalamazoo, MI, have withdrawn as parties to this venture. No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and MCDC intends to file additional written notifications disclosing all changes in membership. On November 13, 2015, MCDC filed its original notification pursuant to Section 6(a) of the Act. The Department of Justice published a notice in the Federal Register pursuant to Section 6(b) of the Act on January 6, 2016 (81 FR 513). The last notification was filed with the Department on July 10, 2017. A notice was published in the Federal Register pursuant to Section 6(b) of the Act on August 15, 2017 (82 FR 38709). Patricia A. Brink, Director of Civil Enforcement, Antitrust Division. [FR Doc. 2017–26215 Filed 12–5–17; 8:45 am] BILLING CODE P E:\FR\FM\06DEN1.SGM 06DEN1

Agencies

[Federal Register Volume 82, Number 233 (Wednesday, December 6, 2017)]
[Notices]
[Page 57616]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-26215]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Antitrust Division


Notice Pursuant to the National Cooperative Research and 
Production Act of 1993--Medical CBRN Defense Consortium

    Notice is hereby given that, on October 13, 2017, pursuant to 
Section 6(a) of the National Cooperative Research and Production Act of 
1993, 15 U.S.C. 4301 et seq. (``the Act''), Medical CBRN Defense 
Consortium (``MCDC'') has filed written notifications simultaneously 
with the Attorney General and the Federal Trade Commission disclosing 
changes in its membership. The notifications were filed for the purpose 
of extending the Act's provisions limiting the recovery of antitrust 
plaintiffs to actual damages under specified circumstances. 
Specifically, Medicago, USA, Durham, NC; Lynntech, Inc., College 
Station, TX; Cepheid, Sunnyvale, CA; Valaria Technical Consultants, 
LLC, Westminster, MD; Integrity Bio, Inc., Camarillo, CA; California 
Institute of Technology, Pasadena, CA; General Atomics, San Diego, CA; 
Conductive Technologies, Inc., York, PA; Dyadic International, Jupiter, 
FL; Excet, Inc., Springfield, VA; INanoBio Inc., Tempe, AZ; SynerGene 
Therapeutics, Inc., Potomac, MD; Rutgers University, New Brunswick, NJ; 
Celdara Medical, LLC, Lebanon, NH; Janus-I Science, Inc., Carlsbad, CA; 
Pharm-Olam International Ltd, Houston, TX; Vaxess Technologies, Inc., 
Allston, MA; HORIBA Instruments, Inc., Edison, NY; Sentinel Analytics 
Software, Inc., Davis, CA; Booz Allen Hamilton, McLean, VA; Tonix 
Pharmaceuticals, New York, NY; Just Biotherapeutics, Inc., Seattle, WA; 
General Electric Company, GE Global Research, Niskayuna, NY; The 
University of North Carolina Chapel Hill, Chapel Hill, NC; and Rector 
and Visitors of the University of Virginia, Charlottesville, VA, have 
been added as parties to this venture.
    Also, Tech62, Fairfax, VA; Joint Research and Development, Inc., 
Stafford, VA; ProModel Corporation, Allentown, PA; and Proteos, 
Kalamazoo, MI, have withdrawn as parties to this venture.
    No other changes have been made in either the membership or planned 
activity of the group research project. Membership in this group 
research project remains open, and MCDC intends to file additional 
written notifications disclosing all changes in membership.
    On November 13, 2015, MCDC filed its original notification pursuant 
to Section 6(a) of the Act. The Department of Justice published a 
notice in the Federal Register pursuant to Section 6(b) of the Act on 
January 6, 2016 (81 FR 513).
    The last notification was filed with the Department on July 10, 
2017. A notice was published in the Federal Register pursuant to 
Section 6(b) of the Act on August 15, 2017 (82 FR 38709).

Patricia A. Brink,
Director of Civil Enforcement, Antitrust Division.
[FR Doc. 2017-26215 Filed 12-5-17; 8:45 am]
BILLING CODE P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.